CompletedPhase 3

Efficacy & Safety of STG320 Sublingual Tablets of HDM Allergen Extracts in Adults and Adolescents With HDM-associated AR

United States, France1,607 participantsStarted 2015-09-29

Plain-language summary

The objective of this study was to assess the efficacy and safety of 12 months of treatment with 300 IR of STG320 sublingual tablets compared with placebo in adults and adolescents with HDM-associated allergic rhinitis.

Who can participate

Age range12 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Main Inclusion Criteria: * Patients with HDM-associated allergic rhinitis (AR) for at least 1 year * Patients sensitized to D. pteronyssinus (D. pte) and/or D. farinae (D. far) defined on skin prick test and HDM-specific serum IgE Main Exclusion Criteria: * A history of rhinitis, rhinoconjunctivitis or asthma to allergens other than HDM, likely to result in rhinitis symptoms during the evaluation periods * Partly controlled or uncontrolled asthma * Controlled asthma requiring controller treatment(s) consistent with GINA 2014 treatment Steps 3 to 5

What they're measuring

Total Combined Score

Timeframe: 12 months

Trial details

NCT IDNCT02443805

SponsorStallergenes Greer

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2018-06-25

Results submitted2019-08-29

View on ClinicalTrials.gov More Rhinitis, Allergic, Perennial trials